We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was trading at $106.13 as of Nov 27th. NVO’s trailing and forward P/E were 35.59 and 27.25 respectively according to Yahoo Finance.
[caption id="attachment_652071" align="aligncenter" width="750"]Novo Nordisk is a global leader in healthcare, renowned for its groundbreaking innovations in diabetes and obesity treatment, notably through products like Ozempic...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.